Annexon Inc (ANNX)

$4.98

-0.22

(-4.23%)

Market is closed - opens 7 PM, 24 Jun 2024

Insights on Annexon Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 77.4% return, outperforming this stock by 39.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.6% return, outperforming this stock by 324.8%

Performance

  • $4.93
    $5.30
    $4.98
    downward going graph

    1.0%

    Downside

    Day's Volatility :6.98%

    Upside

    6.04%

    downward going graph
  • $1.57
    $8.40
    $4.98
    downward going graph

    68.47%

    Downside

    52 Weeks Volatility :81.31%

    Upside

    40.71%

    downward going graph

Returns

PeriodAnnexon IncSector (Health Care)Index (Russel 2000)
3 Months
-26.76%
0.9%
0.0%
6 Months
24.19%
8.7%
0.0%
1 Year
37.57%
10.9%
0.0%
3 Years
-79.24%
17.4%
-23.0%

Highlights

Market Capitalization
530.1M
Book Value
$2.9
Earnings Per Share (EPS)
-1.46
Wall Street Target Price
16.4
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-28.6%
Return On Equity TTM
-50.6%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-128.9M
Diluted Eps TTM
-1.46
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.98
EPS Estimate Next Year
-1.05
EPS Estimate Current Quarter
-0.34
EPS Estimate Next Quarter
-0.36

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Annexon Inc(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
12
12
Hold
1
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 229.32%

Current $4.98
Target $16.40

Technicals Summary

Sell

Neutral

Buy

Annexon Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Annexon Inc
Annexon Inc
2.05%
24.19%
37.57%
-79.24%
-76.55%
Moderna, Inc.
Moderna, Inc.
-18.32%
40.58%
10.72%
-39.74%
850.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
7.05%
24.38%
35.05%
97.21%
236.95%
Novo Nordisk A/s
Novo Nordisk A/s
5.92%
38.21%
77.43%
245.57%
453.56%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.73%
15.66%
34.62%
148.17%
158.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Annexon Inc
Annexon Inc
NA
NA
NA
-0.98
-0.51
-0.29
NA
2.9
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.7
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.93
30.93
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.78
49.78
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.61
30.61
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Annexon Inc
Annexon Inc
Buy
$530.1M
-76.55%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$51.5B
850.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$115.3B
236.95%
30.93
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$644.0B
453.56%
49.78
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.7B
158.93%
30.61
39.46%

Institutional Holdings

  • FMR Inc

    10.14%
  • Bain Capital Life Sciences Investors, LLC

    9.42%
  • SATTER MANAGEMENT CO., L.P.

    8.01%
  • Bvf Inc

    7.57%
  • Redmile Group, LLC

    5.96%
  • Point72 Asset Management, L.P.

    5.58%

Company Information

our mission is to develop disease-modifying therapeutics for patients suffering from neurological disorders such as huntington’s disease and alzheimer’s disease by targeting complement-mediated neurodegeneration (cmnd).

Organization
Annexon Inc
Employees
70
CEO
Mr. Douglas Love Esq., J.D.
Industry
Health Technology

FAQs